Search Results - "Cheung, Jeanne"
-
1
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Published in Nature communications (21-02-2017)“…Expression of PD-L1, the ligand for T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradication by the immune…”
Get full text
Journal Article -
2
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
Published in Journal for immunotherapy of cancer (01-10-2020)“…BackgroundCancer immunotherapy has evolved from interferon-alpha (IFNα) and interleukin-2 in the 1980s to CTLA-4 and PD-1/PD-L1 checkpoint inhibitors (CPIs),…”
Get full text
Journal Article -
3
A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R
Published in The Journal of immunology (1950) (01-06-2002)“…Abstract IL-23 is a heterodimeric cytokine composed of the IL-12p40 “soluble receptor” subunit and a novel cytokine-like subunit related to IL-12p35, termed…”
Get full text
Journal Article -
4
Role of PD-1 during effector CD8 T cell differentiation
Published in Proceedings of the National Academy of Sciences - PNAS (01-05-2018)“…PD-1 (programmed cell death-1) is the central inhibitory receptor regulating CD8 T cell exhaustion during chronic viral infection and cancer. Interestingly,…”
Get full text
Journal Article -
5
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Published in Science (American Association for the Advancement of Science) (31-03-2017)“…Programmed cell death–1 (PD-1) is a coinhibitory receptor that suppresses T cell activation and is an important cancer immunotherapy target. Upon activation by…”
Get full text
Journal Article -
6
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Published in Immunity (Cambridge, Mass.) (15-03-2016)“…Targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) can induce regression of tumors bearing activating mutations in the Ras pathway but…”
Get full text
Journal Article -
7
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Published in Nature cancer (01-07-2020)“…Inhibiting the programmed death-1 (PD-1) pathway is one of the most effective approaches to cancer immunotherapy, but its mechanistic basis remains…”
Get full text
Journal Article -
8
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses
Published in The Journal of immunology (1950) (15-10-2018)“…Immunotherapy with checkpoint inhibitors has proved to be highly effective, with durable responses in a subset of patients. Given their encouraging clinical…”
Get full text
Journal Article -
9
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6
Published in The Journal of clinical investigation (01-05-2006)“…Uncontrolled mucosal immunity in the gastrointestinal tract of humans results in chronic inflammatory bowel disease (IBD), such as Crohn disease and ulcerative…”
Get full text
Journal Article -
10
Abstract 4898: Effects of chemotherapeutic agents on the tumor immune microenvironment
Published in Cancer research (Chicago, Ill.) (15-07-2016)“…Abstract Immunotherapeutic agents have shown dramatic success in oncology in recent years and several have been approved in melanoma and lung cancer. One…”
Get full text
Journal Article -
11
IL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo
Published in Immunity (Cambridge, Mass.) (01-12-2001)“…We have characterized a cytokine produced by Th2 cells, designated as IL-25. Infusion of mice with IL-25 induced IL-4, IL-5, and IL-13 gene expression. The…”
Get full text
Journal Article -
12
Abstract 4905: Effects of MAPK pathway inhibitors in the tumor immune microenvironment
Published in Cancer research (Chicago, Ill.) (15-07-2016)“…Abstract Immunotherapeutic agents have shown great promise in the clinic in recent years and this has led to their approval as single agents or as immune…”
Get full text
Journal Article -
13
MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
Published in Journal for immunotherapy of cancer (07-11-2013)“…Pharmacological inhibition of the MAPK pathway with MEK or BRAF antagonists has proved successful in inducing regression of melanoma tumors bearing the…”
Get full text
Journal Article -
14
Masoprocol (nordihydroguaiaretic acid): a new antihyperglycemic agent isolated from the creosote bush ( Larrea tridentata)
Published in European journal of pharmacology (03-04-1998)“…An ethnomedically-driven approach was used to evaluate the ability of a pure compound isolated from the creosote bush ( Larrea tridentata) to lower plasma…”
Get full text
Journal Article -
15
Novel terpenoid-type quinones isolated from Pycnanthus angolensis of potential utility in the treatment of type 2 diabetes
Published in The Journal of pharmacology and experimental therapeutics (01-02-1999)“…Using an ethnomedical-based drug discovery program, two previously unknown compounds (SP-18904 and SP-18905) from Pycnanthus angolensis were isolated that…”
Get more information
Journal Article -
16
IL-27, a Heterodimeric Cytokine Composed of EBI3 and p28 Protein, Induces Proliferation of Naive CD4 + T Cells
Published in Immunity (Cambridge, Mass.) (01-06-2002)“…An efficient Th1-driven adaptive immune response requires activation of the T cell receptor and secretion of the T cell stimulatory cytokine IL-12 by activated…”
Get full text
Journal Article -
17
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R
Published in The Journal of immunology (1950) (01-06-2002)“…IL-23 is a heterodimeric cytokine composed of the IL-12p40 "soluble receptor" subunit and a novel cytokine-like subunit related to IL-12p35, termed p19. Human…”
Get full text
Journal Article -
18
A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12R{beta}1 and a Novel Cytokine Receptor Subunit, IL-23R
Published in The Journal of immunology (1950) (01-06-2002)Get full text
Journal Article